Behind Biotech

From mRNA vaccines to gene and cell therapies, biotech is changing the world. But who are the leaders behind these and other biotech innovations and what makes them so passionate about what they do? In the Behind Biotech Podcast, we’re exploring not only disruptive trends in biotechnology, but also the stories of the ‌founders,‌ ‌researchers, executives,‌ ‌patients,‌ ‌investors,‌ ‌and‌ ‌other‌ ‌leaders‌ ‌who‌ ‌dedicate‌ ‌their‌ ‌lives‌ ‌to‌ ‌improve healthcare through biotech.

Behind Biotech is a business podcast hosted by Jingyi Liu, Eric Dai, with 13 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Jingyi Liu, Eric Dai hosts Behind Biotech, a business show with 13 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Behind Biotech

  Season 2| China: Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy

  Aug 3, 202232 minS0

  <p>Hong Tang Biography</p> <p>Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified internal medicine physician with more than 15 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH. OnQuality Pharmaceuticals is designing targeted cancer supportive care treatments aimed at preventing and treating the intolerable side effects caused by specific cancer drugs. Their mission is to make fighting cancer easier by alleviating the side effects of an...

  ListenShow Notes
• 

  Episode #4

  Season 2 | China: George Chen on Building a "In China, for Global" Biotech

  Jun 28, 202236 minS2

  <p>George Chen Biography</p> <p>George Chen, MD MBA, is an oncologist by training with a successful track record in the world of global pharmaceutical companies.  Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson, BeiGene, and Astra Zeneca.  At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs.  His medical degree is...

  ListenShow Notes
• 

  Episode #3

  Season 2| China: Bing Yuan on Global Outlicensing of Chinese Biotech

  Jun 2, 202231 minS2

  <p>Dr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals. As a senior executive from the beginning, he helped to build the company from scratch to successful IPO and a fully integrated biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D...

  ListenShow Notes
• 

  Episode #2

  Season 2| China: Shawn Xiang on Building China's Rare Disease Ecosystem

  May 8, 202228 minS2

  <p>Shawn Xiang Biography</p> <p>Dr. Xiang is the CEO of Rarestone Group, a company building the first rare disease ecosystem in China. Dr. Xiang has more than 15 years of leadership experience in pharmaceutical and medical device industries. Prior to RareStone, Shawn was the General Manager of Greater China and Emerging Asia Region at Abbott Diabetes Care, where he led his team and successfully launched FreeStyle Libre in China, Korea and Southeast Asia markets and achieved hyper-growth consecutively over the years. Shawn also led his team to build an ecosystem for patients living with Type 1 Diabetes, through strong collaboration...

  ListenShow Notes
• 

  Episode #1

  Season 2| China: Brad Loncar on Investment Risk and Innovation Drivers in Chinese Biotech

  Apr 14, 202252 minS2

  <p>Brad Loncar Biography</p> <p>Brad Loncar is a biotechnology industry investor and CEO of Loncar Investments. He is the creator of two Nasdaq-listed biotech focused exchange-traded funds. Brad previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, Nasdaq.com, and contributes opinion pieces to Endpoints News. He’s also the co-host of Biotech Clubhouse, which recaps the week’s biot...

  ListenShow Notes

Recent guests on Behind Biotech. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.